XXXX gene-460 C/T polymorphism is a biomarker for @entity263 .

@entity1 @entity263 @entity7 @entity5 @entity377
OBJECTIVES: To use the Bst U I polymorphism as a genetic marker in the search for the association between @entity1 with @entity263 and normal control subjects. The formation or progression of @entity263 is presumed to be associated with a polymorphism of the @entity7 ( @entity7 ) gene. The most frequently seen polymorphism is Bst U I (C to T) located at the -460th @entity377 upstream of the @entity7 gene. METHODS: A normal control group of 119 healthy @entity1 and 96 @entity1 with @entity263 were examined. The polymorphism was seen after polymerase chain reaction-based restriction analysis. RESULTS: The analysis revealed significant differences between normal individuals and @entity1 with @entity5 (P <0.001). Also, the distribution of the "TT" homozygote in the @entity1 group was greater than that in the control group. The odds ratio per copy of the "T" allele was 2.3 (95% confidence interval 1.4 to 3.8) and was 2.2 (95% CI 1.3 to 3.8) when adjusted for age. No statistically significant differences in clinical stage or grade were found. We also categorized the 54 @entity1 who received hormonal therapy into response and nonresponse groups, but no statistically significant differences between these two groups were revealed (P = 0.110, Fisher's exact test). CONCLUSIONS: The Bst U I polymorphism of the @entity7 gene is a suitable genetic marker of @entity263 but cannot be used in the prediction of the outcome of @entity1 who have received hormonal therapy.
